HeXun Biosciences Co., Ltd. (TPEX:6986)
Taiwan
· Delayed Price · Currency is TWD 62.30
-2.00 (-3.11%)
Apr 29, 2026, 1:41 PM CST
HeXun Biosciences Income Statement
Financials in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| Revenue | 293.23 | 286.42 | 130.57 | 49.47 | - |
| Revenue Growth (YoY) | 2.38% | 119.36% | 163.94% | - | - |
| Cost of Revenue | 26.95 | 25.75 | 16.84 | 4.86 | - |
| Gross Profit | 266.28 | 260.67 | 113.73 | 44.61 | - |
| Selling, General & Admin | 49.09 | 39.57 | 33.14 | 14.23 | 5.95 |
| Research & Development | 99.18 | 65.37 | 53.22 | 39.36 | 44.71 |
| Operating Expenses | 148.27 | 104.94 | 86.36 | 53.59 | 50.66 |
| Operating Income | 118.01 | 155.73 | 27.37 | -8.98 | -50.66 |
| Interest Expense | -1.11 | -1.18 | -1.85 | -1.64 | -1.57 |
| Interest & Investment Income | 6.75 | 4.41 | 2.79 | 0.46 | 0.03 |
| Currency Exchange Gain (Loss) | 0.28 | -0.79 | 0.53 | 0.02 | - |
| Other Non Operating Income (Expenses) | 3.6 | 3.3 | 4.7 | 4.93 | 9.01 |
| EBT Excluding Unusual Items | 127.52 | 161.48 | 33.54 | -5.21 | -43.19 |
| Gain (Loss) on Sale of Assets | -1.62 | -0.01 | -0.05 | 0.02 | 0.2 |
| Other Unusual Items | 0.03 | - | - | - | - |
| Pretax Income | 125.93 | 161.47 | 33.49 | -5.19 | -42.99 |
| Income Tax Expense | 14.02 | 14.25 | - | - | - |
| Net Income | 111.91 | 147.22 | 33.49 | -5.19 | -42.99 |
| Net Income to Common | 111.91 | 147.22 | 33.49 | -5.19 | -42.99 |
| Net Income Growth | -23.99% | 339.62% | - | - | - |
| Shares Outstanding (Basic) | 46 | 46 | 45 | 38 | 31 |
| Shares Outstanding (Diluted) | 46 | 46 | 45 | 38 | 31 |
| Shares Change (YoY) | -0.03% | 1.61% | 20.81% | 22.92% | - |
| EPS (Basic) | 2.43 | 3.20 | 0.74 | -0.14 | -1.41 |
| EPS (Diluted) | 2.43 | 3.20 | 0.74 | -0.14 | -1.41 |
| EPS Growth | -24.06% | 332.90% | - | - | - |
| Free Cash Flow | 136.61 | 83.63 | 22.42 | 10 | -35.5 |
| Free Cash Flow Per Share | 2.97 | 1.82 | 0.49 | 0.27 | -1.16 |
| Dividend Per Share | 0.220 | - | - | - | - |
| Gross Margin | 90.81% | 91.01% | 87.10% | 90.18% | - |
| Operating Margin | 40.24% | 54.37% | 20.96% | -18.15% | - |
| Profit Margin | 38.16% | 51.40% | 25.65% | -10.49% | - |
| Free Cash Flow Margin | 46.59% | 29.20% | 17.17% | 20.22% | - |
| EBITDA | 141.68 | 175.88 | 43.12 | 2.58 | -41.87 |
| EBITDA Margin | 48.32% | 61.41% | 33.03% | 5.21% | - |
| D&A For EBITDA | 23.68 | 20.15 | 15.75 | 11.56 | 8.8 |
| EBIT | 118.01 | 155.73 | 27.37 | -8.98 | -50.66 |
| EBIT Margin | 40.24% | 54.37% | 20.96% | -18.15% | - |
| Effective Tax Rate | 11.13% | 8.82% | - | - | - |
Source: S&P Capital IQ. Standard template. Financial Sources.